The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 38 | — | 20.1x | Near average | |
Growth | 7 | -30.0% | 5.6% | Below average | |
Quality | 37 | -73.5% | 7.6% | Near average | |
Safety | 70 | 0.7x | 0.4x | Above average | |
Capital Return | 94 | — | 2.19% | Above average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Evommune, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Evommune, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The average price target for Evommune shares has experienced slight volatility over the past 30 days, decreasing by 2.87% before partially rebounding with a 2.26% increase in the last week to settle at 48.4 dollars. This relative stability in forecasts, with the number of analysts holding steady at two, reflects a state of cautious anticipation despite the significant gap between the current price (19.82 dollars) and the lowest price target (40 dollars), indicating structural optimism regarding the stock's future despite short-term fluctuations.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.